Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy

Köş, Fahriye Tuğba; Şendur, Mehmet Ali Nahit; Aksoy, Sercan; Sezer, Sevilay; Civelek, Birol; Yazıcı, Ozan; Yaman, Samet; Eren, Tulay; Zengi̇n, Nurullah

doi:10.3109/0886022x.2013.777929

Cited by 13 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Furthermore, in several malignancies, the serum cystatin C levels are elevated, probably related to its nature as a cysteine protease inhibitor [15] and this phenomenon is associated with more aggressive forms of tumors [16]. Our data are consistent with those from other studies reporting the serum cystatin C levels increase in cancer patients.…”

Section: Discussionsupporting

confidence: 91%

Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy

Cavalcanti

Barchiesi

Cerasuolo

et al. 2016

Analytical Cellular Pathology

View full text Add to dashboard Cite

Objectives. Serum cystatin C seems to be an accurate marker of glomerular filtration rate (GFR) compared to serum creatinine. The aim of this work was to explore the possibility of using serum cystatin C instead of serum creatinine to early predict renal failure in cancer patients who received platinum based chemotherapy. Design and Methods. Serum creatinine, serum cystatin C concentrations, and GFR were determined simultaneously in 52 cancer patients received carboplatin-based or cisplatin-based chemotherapy. Serum creatinine was assayed on Cobas C6000-Roche, serum cystatin C assay was performed on AIA 360-Tosoh, and GFR was determined in all patients, before the first cycle of chemotherapy and before the subsequent administrations. Results. In the overall series, for the prediction of a fall of GFR < 80 mL/min/1.73 m2, the AUC of the ROC curve for cystatin C was 0,667 and the best threshold was 1.135 mg/L (sensitivity 90.5%, specificity 61.1%). For a GFR fall < 60 mL/min/1.73 m2, the AUC of ROC curve for cystatin C was 74.3% and the best threshold was 1.415 mg/L (sensitivity 66.7%, specificity 73.2%). Conclusions. Baseline cystatin C values were not able to predict renal failure during subsequent treatment. In conclusion, serum cystatin C is not a reliable early marker to efficiently predict renal failure in patients receiving chemotherapy.

show abstract

Section: Discussionsupporting

confidence: 91%

Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy

Cavalcanti

Barchiesi

Cerasuolo

et al. 2016

Analytical Cellular Pathology

View full text Add to dashboard Cite

show abstract

“…Several novel biomarkers such as NGAL, cystatin‐C, and KIM‐1 have been proposed for early detection of cisplatin associated AKI. Although conflicting, it seems that urine NGAL may be the best marker among them [Gaspari et al ., ;Lin et al ., ; Nan‐Ya et al ., ; Mishra et al ., ; Kos et al ., , ]. Therefore, we assessed urine NGAL in this study.…”

Section: Discussionmentioning

confidence: 99%

Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double‐Blinded, Placebo‐Controlled Clinical Trial

Shahbazi

Sadighi

Dashti‐Khavidaki

et al. 2015

Phytotherapy Research

View full text Add to dashboard Cite

Despite several introduced preventive modalities, cisplatin nephrotoxicity remains a clinical problem. Some in vitro and in vivo studies have addressed the protective effects of silymarin against cisplatin nephrotoxicity. This study evaluated the effects of silymarin administration on cisplatin nephrotoxicity as the first human study. During this pilot, randomized, double-blinded, placebo-controlled clinical trial, the effect of oral silymarin 420 mg daily in three divided doses starting 24-48 h before the initiation of cisplatin infusion and continuing to the end of three 21-day cisplatin-containing chemotherapy courses on cisplatin-induced renal electrolytes wasting and kidney function were assessed. Cisplatin-associated acute kidney injury (AKI) occurred in 8% of the patients. Urine neutrophil gelatinase-associated lipocalin to urine creatinine ratio (NGAL/Cr) and urinary magnesium and potassium wasting increased significantly after cisplatin infusion in both groups. Significant positive correlation was found between cumulative dose of cisplatin and urine NGAL/Cr after three courses of cisplatin infusion. Incidence of AKI and the magnitude of urinary magnesium and potassium wasting did not differ between silymarin and placebo groups. No adverse reaction was reported by silymarin administration. Prophylactic administration of conventional form of silymarin tablets could not prevent cisplatin-induced urine electrolyte wasting or renal function impairment.

show abstract

“…The CKD-EPI equation is now accepted the most accurate estimating method for GFR prediction [9,10]. Matsushita et al investigated more than 1 million adults from 25 general population cohorts and they found that CKD EPI had better outcomes than MDRD to predict mortality but these populations had especially chronic kidney disease or end stage renal disease [11]. One of the recent studies about this topic published by Janowitz et al They investigated about 2500 patients who had GFR results calculated with chromium-51 (51Cr) EDTA excretion in cancer patients.…”

Section: Discussionmentioning

confidence: 99%

Correlations between estimating GFR methods and oncological outcomes during cancer chemotherapy

et al. 2019

View full text Add to dashboard Cite

Background: Glomerular filtration rate (GFR) measurements are critical in patients with cancer. A variety of methods are used to calculate the estimated GFR. The aim of this study is to investigate whether there is a correlation between these methods and oncologic outcomes according to the stage and treatment agents. Methods: A total of 153 patients were retrospectively recruited. All GFR measurement methods was determined in all patients, before the first cycle of chemotherapy and before the subsequent administrations. Results: In the study population 40% of whom received platinum-based chemotherapy. In this group, overall survival was statistically significant in patients with a CKD-EPI creatinine value of 65 or greater (p:0.023). When we separated the arms according to the stage, there was no relationship between CKD-EPI Cystatin C and progression-free survival in metastatic patients (p: 0.13). In the non-metastatic group, median DFS was 7 months and OS was 13.9 months in patients with CKD-EPI Cystatine C level above 45 (p:0.005). Conclusions: Both CKD-EPI creatinine and CKD-EPI cystatin C were significantly associated with overall survival and diseasefree survival in patients receiving platinum-based chemotherapy. When assessed according to the stage, there was a general survival relationship with CKD-EPI cystatin C in the non-metastatic group and in the other groups there was no significant correlation with the estimated GFR measurements.

show abstract

Evaluation of the Renal Function Using Cystatin C Level in the Patients Receiving Cisplatin-Based Chemotherapy

Cited by 13 publications

References 23 publications

Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy

Correlation of Serum Cystatin C with Glomerular Filtration Rate in Patients Receiving Platinum-Based Chemotherapy

Effect of Silymarin Administration on Cisplatin Nephrotoxicity: Report from A Pilot, Randomized, Double‐Blinded, Placebo‐Controlled Clinical Trial

Correlations between estimating GFR methods and oncological outcomes during cancer chemotherapy

Contact Info

Product

Resources

About